IAGIM RESEARCH
THE INTERNATIONAL GLIMER I, II & III MS STUDY (Ongoing 2010 - 2025 \| Fifteen Year GLIMER Project - Extended 2019)
Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.) Chief Scientist IAGIM Institute and CEO LIGroup




Jeremy David Block BSc. (Eng.), MSc.(WCU), (Micro/Stats), D.Pharm (Wits)., PHD (Neuro IAGIM. U.) Part Eight - 2019/7 - Total Parts 20 - Pages 110) Background: Prof. Jeremy D. Block served for the duration of the development of COP 1 as a senior medical/pharmaceutical researcher and part of the Teva COP 1 innovative research team in the early nineties that rapidly developed Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM). As Chief Scientist as well as Teva Group Scientific Research Auditor, and by touching each and every part of Teva's overall scientific team Teva rapidly attained ND registration with the FDA under Dr. J. D. Block scientific and technical guidence and regulatory department training and overview.

ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month"

Dictionary of Cancer Terms
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

| Global Work Shops |

Top of Page
\| Home \| Overview \| Contact Us \| IAGIM Online \| New Journals \|
\| Worldwide Web sites \| Partnerships \| Drug ID List \| DOPs \| SOP Index \| SI Assays \| Site Map \|
\| Shipping \| By FastTrack \| Data Protection \| \| Fast Service \| Press Reports \| Copyright LIG © 2019/17 Locum International Inc. All Rights Reserved. Read our Terms & Conditions of Use - \| TEL MESSAGE: 24 x 7 - \| - - +1-561-865-6147- \|